Related Party Transactions (Details Narrative)							1 Months Ended		11 Months Ended	12 Months Ended
	Oct. 17, 2017 USD ($) $ / shares shares	Jul. 10, 2017 USD ($) $ / shares shares	Jul. 10, 2017 USD ($) $ / shares shares	Feb. 15, 2017 USD ($) $ / shares shares	Jul. 05, 2016 USD ($) shares	Jun. 16, 2016 USD ($) $ / shares shares	Oct. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) ft² $ / shares	Dec. 31, 2017 USD ($) ft² $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) shares	Feb. 17, 2017 $ / shares	May 13, 2016 $ / shares
Carrying value of convertible notes											$ 1,032,000
Common shares issued value										45,068,000	18,606,000	$ 33,897,000
Intrinsic value of equity										3,100,000
Loss on debt extinguishment										$ 2,799,000
Markup rate on allocated costs										5.00%
Interest rate charged on unpaid and overdue invoices										15.00%
Receivables from related party									$ 2,100,000	$ 2,100,000
Rent per month										$ 5,050
Area of office space square feet | ft²									900	900
Alfred D. Kingsley [Member]
Common shares issued | shares										200,000
Stock price per share | $ / shares									$ 2.00	$ 2.00
Common stock shares converted | shares										300,000
Common stock shares converted price per share | $ / shares									2.81	$ 2.81
Common Stock [Member]
Common shares issued | shares	11,057,693		4,924,542	7,453,704	1,098,326	7,322,176	1,600,000	2,607,401		18,511,000	8,420,000	10,738,000
Common shares issued value	$ 26,700,000		$ 15,200,000	$ 18,500,000	$ 2,200,000	$ 16,400,000	$ 5,100,000	$ 8,600,000		$ 45,068,000	$ 18,606,000	$ 33,897,000
Price per share on NYSE mkt | $ / shares		$ 3.09	$ 3.09
Stock price per share | $ / shares	$ 2.60			$ 2.70		$ 2.39	$ 3.19	$ 3.29
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, noncontrolling owners		21.20%	21.20%
OncoCyte Corporation [Member]
Price per share on NYSE mkt | $ / shares									$ 4.65	$ 4.65			$ 4.85
Repayments of related party debt									$ 1,600,000
Ascendance Biotechnology, Inc [Member]
Receivables from related party									$ 200,000	$ 200,000
Asterias Biotherapeutics [Member]
Price per share on NYSE mkt | $ / shares									$ 2.25	$ 2.25	$ 4.60			$ 3.02
Receivables from related party											$ 300,000
Net payables to related party									$ 33,000	$ 33,000
AgeX Therapeutics, Inc [Member]
Additional common shares purchased | shares										421,500
Additional common stock shares purchased price per share | $ / shares									$ 2.00	$ 2.00
Common stock issued to unaffiliated and existing investors | shares										300,000
Common stock price per share issued to unaffiliated and existing investors | $ / shares									$ 2.81	$ 2.81
Maximum [Member] | OncoCyte Corporation [Member]
Term of payment										30 days
Cell Cure Neurosciences, Ltd. [Member]
Carrying value of convertible notes									$ 1,865,000	$ 1,865,000
Amount of accrued interest									2,544,000	2,544,000
Unamortized debt discount									$ 679,000	$ 679,000
Cell Cure Neurosciences, Ltd. [Member] | Hadasit Bio-Holdings, Ltd [Member] | Common Stock [Member]
Common shares issued | shares		1,220,207
Common shares issued value		$ 3,800,000
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member]
Convertible notes bear a stated interest rate									3.00%	3.00%
Conversion price | $ / shares									$ 20.00	$ 20.00
Accrued interest, payable period										3 years
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Hadasit Bio-Holdings, Ltd [Member] | Common Stock [Member]
Common shares issued | shares		2,776,662
Common shares issued value		$ 8,600,000
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Minimum [Member]
Estimated fair market value per share | $ / shares										$ 28.00
Intrinsic value per share | $ / shares										$ 8
Effective annual interest rate									11.00%	11.00%
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Maximum [Member]
Estimated fair market value per share | $ / shares										$ 40.00
Intrinsic value per share | $ / shares										$ 20
Effective annual interest rate									23.00%	23.00%